Literature DB >> 1939103

Covalent linkage between nucleotides and platelet-derived endothelial cell growth factor.

K Usuki1, K Miyazono, C H Heldin.   

Abstract

Platelet-derived endothelial cell growth factor (PD-ECGF) is a 45-kDa peptide mitogen which is present in platelets and placenta and produced by certain cultured cell lines. Immunoprecipitation of A431 cells metabolically labeled with [32P]orthophosphate revealed the incorporation of 32P radioactivity into PD-ECGF. Phosphoamino acid analysis showed that serine residues of PD-ECGF were phosphorylated in vivo. Forskolin, 12-O-tetradecanoylphorbol-13-acetate, and epidermal growth factor had no effect on the in vivo phosphorylation of PD-ECGF. Moreover, incubation of pure PD-ECGF with [gamma-32P]ATP led to labeling of PD-ECGF. Optimal labeling was achieved by incubation at 95 degrees C for 5 min in the presence of sodium dodecyl sulfate, dithiothreitol, and Mg2+ or Mn2+. PD-ECGF was also labeled with [2,8-3H]ATP, [2,5',8-3H]ATP, or [alpha-32P]ATP. ATP and GTP were the preferred nucleotide substrates by comparison with other nucleotides and related components. Partial amino acid hydrolysis liberated a significant amount of O-[32P]phosphoserine from PD-ECGF labeled in vitro with [gamma-32P] ATP. Furthermore, 32P-radiolabeled nucleotides were released after snake venom phosphodiesterase or piperidine treatment from PD-ECGF labeled in vitro with [alpha-32P]ATP or [gamma-32P]ATP, as well as from PD-ECGF labeled in vivo with [32P]orthophosphate. These data indicate that serine residues of PD-ECGF can be covalently linked to phosphate groups of nucleotides, resulting in a nucleotidylated protein. The functional significance of this post-translational modification remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1939103

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Human platelet-derived endothelial cell growth factor is homologous to Escherichia coli thymidine phosphorylase.

Authors:  G J Barton; C P Ponting; G Spraggon; C Finnis; D Sleep
Journal:  Protein Sci       Date:  1992-05       Impact factor: 6.725

Review 2.  The biology of radioresistance: similarities, differences and interactions with drug resistance.

Authors:  S N Powell; E H Abraham
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 3.  Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis.

Authors:  N S Brown; R Bicknell
Journal:  Biochem J       Date:  1998-08-15       Impact factor: 3.857

Review 4.  Thymidine phosphorylase: A potential new target for treating cardiovascular disease.

Authors:  Wei Li; Hong Yue
Journal:  Trends Cardiovasc Med       Date:  2017-10-20       Impact factor: 6.677

Review 5.  Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy.

Authors:  L Griffiths; I J Stratford
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 6.  The dual role of thymidine phosphorylase in cancer development and chemotherapy.

Authors:  Annelies Bronckaers; Federico Gago; Jan Balzarini; Sandra Liekens
Journal:  Med Res Rev       Date:  2009-11       Impact factor: 12.944

7.  Thymidine phosphorylase promotes malignant progression in hepatocellular carcinoma through pentose Warburg effect.

Authors:  Qiang Zhang; Yuan Qin; Jianmin Zhao; Yuanhao Tang; Xuejiao Hu; Weilong Zhong; Mimi Li; Shumin Zong; Meng Li; Honglian Tao; Zhen Zhang; Shuang Chen; Huijuan Liu; Lan Yang; Honggang Zhou; Yanrong Liu; Tao Sun; Cheng Yang
Journal:  Cell Death Dis       Date:  2019-01-17       Impact factor: 8.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.